SOLIGENIX, INC.
SNGX · Pharmaceutical Preparations
Latest available SEC filing: 4 ·
Latest disclosures
-
Zeldis Jerome B: Form 4
Insider disclosure · Filed · Report period 12 Oct 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
Company details and SEC sources
CIK 0000812796 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- SNGX on Nasdaq
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 29 Emmons Drive, Suite B 10, Princeton, NJ, 08540
- Incorporated in
- DE
- Fiscal year end
- 31 December
- Former names on EDGAR
- DOR BIOPHARMA INC (to 29 Sep 2009), ENDOREX CORP (to 24 Oct 2001), IMMUNOTHERAPEUTICS INC (to 30 Apr 1996)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields